DCD Organ Preservation Perfusion Solution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The shortage of available organs for transplantation, particularly from Donation After Cardiac Death (DCD) donors, is exacerbated by warm ischemia-induced injuries and reperfusion damage, which limits the viability and suitability of DCD organs for transplantation.
Innovation Solution
A perfusion solution comprising specific metabolic agents, antioxidant agents, and membrane stabilizers, used in combination with hypothermic machine perfusion, helps prevent further damage, restore the organ's antioxidant system, stabilize cellular structures, and improve energy stores, thereby enhancing the viability and preservation time of marginal donor organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If organs are harvested from DCD donors after cessation of cardiopulmonary function, then the organ donor pool is expanded, but warm ischemia injury and reperfusion damage occur
Solution Approach 1:
The patent applies preliminary action by administering protective agents (antioxidants, anti-apoptotics, metabolic substrates) to the organ before transplantation to preemptively counteract the harmful effects of warm ischemia and reperfusion injury. This prepares the organ in advance to withstand the inevitable ischemic stress from DCD donation.
Solution Approach 2:
The patent converts the harmful reperfusion process into a beneficial one by carefully controlling the reperfusion conditions and administering protective agents that transform the potentially damaging reperfusion into a restorative process that reduces injury and improves organ viability.
2Reliability
If cold preservation is used to reduce ischemia injury, then organ viability is improved, but preservation time is still limited
Solution Approach 1:
The patent applies parameter changes by modifying the preservation solution composition (adding antioxidants, anti-apoptotics, metabolic substrates) and adjusting preservation conditions to extend the viable preservation time beyond conventional limits, allowing marginal organs to remain transplantable for longer periods.
Solution Approach 2:
The patent uses a composite preservation solution containing multiple active ingredients (antioxidants, anti-apoptotics, metabolic substrates, and conventional preservation agents) that work synergistically to protect the organ from multiple types of injury simultaneously, thereby extending preservation time while maintaining viability.
3Use of energy by moving object
If reperfusion is performed to restore blood flow to the organ, then organ function is restored, but ischemia-reperfusion injury occurs
Solution Approach 1:
The patent applies preliminary anti-action by administering protective agents before reperfusion to preemptively block the harmful pathways of reperfusion injury (oxidative stress, apoptosis, inflammation) while allowing the beneficial restoration of blood flow and organ function to proceed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution significantly expands the organ donor pool, increases the number of transplants, and reduces patient wait times by improving the viability of DCD organs, making them suitable for transplantation and extending the preservation time for better recipient matching.
Implementation Method 1
antioxidant agents, and membrane stabilizers, used in combination with hypothermic machine perfusion, helps prevent further damage, restore the organ's antioxidant system
Implementation Method 2
hypothermic machine perfusion, involves continuous perfusion of the organ with a perfusate maintained at a temperature between 4° C. and 8° C.
Implementation Method 3
perfusion solution comprising specific metabolic agents, antioxidant agents, and membrane stabilizers
Data Source
AI summary
The present invention provides a perfusion solution comprising specific metabolic agents, antioxidant agents, and membrane stabilizer agents that can help improve preservation, organ viability, and in some cases recover organs that would otherwise being unusable for transplantation. In a further embodiment, the perfusion solution can be used in combination with hypothermic machine perfusion. It has been found that combination of the perfusion solution and hypothermic machine perfusion can help prevent or reduce further damage to the organ and restore the organ's anti-oxidant system, stabilize the cellular cytoskeleton and cellular membranes, inhibit arachidonic acid pathway, provide oncotic support, reduce interstitial edema formation, and help restore energy stores within the organ. As a result, the method can be used to improve the viability of otherwise marginal donor organs.